Allergy & ImmunologyAutoimmune DiseasesCD19 CAR T-cell therapy
CD19 CAR T-cell Therapy Without Lymphodepletion Shows Promise in Pemphigus Vulgaris: Insights from the RESET-PV Trial
By MedXY|Aug 2, 2026
Early results from the RESET-PV trial indicate that CD19 CAR T-cell therapy without lymphodepleting preconditioning is feasible and safe for pemphigus vulgaris, offering significant clinical improvement and durable B-cell depletion.
